

FOR IMMEDIATE RELEASE

## **IntegraGen announces successful completion of a € 3.7 million capital increase**

---

**EVRY, FRANCE, 3 February 2017** – IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), a company specializing in the decoding of the human genome and performing interpretable genomic analyses for academic and private laboratories and a developer of diagnostic tools in oncology, today announced that it has successfully completed a capital increase with cancellation of preferential subscription rights, reserved for a category of investors in the amount of € 3.7 million.

### Objectives of Fundraising

The funds received will permit IntegraGen to accelerate its development by supporting the deployment of the following new activities:

- Launch of kit production **miRpredX**: commercialization of a predictive diagnostic kit for response to anti-EGFR treatment for patients with metastatic colorectal cancer.
- Development of ICE (Interpretation of Clinical Exome), a software tool for interpreting clinical genomics data in cancer patients

The funds will also enable IntegraGen's genomic services platforms to be strengthened with newer technologies.

The completion of these projects will be a significant turning point in terms of the Company's activities.

### Overview of the capital increase

At the end of the transaction, IntegraGen will issue 1,466,622 new shares with a par value of € 1 each at a unit price of € 2.53, including issue premium, resulting in an increase in Capital totaling € 3,710,553.66. The unit price of 2.53 euros represents a discount of 17% compared to the closing price of 2 February 2017 (3.06 euros).

The capital increase was implemented by decision of the Board of Directors of 2 February 2017 in accordance with the delegations granted to it by the Combined General Meeting of Shareholders of 9 June 2016.

The capital increase was made by issuing common shares without preferential subscription rights in connection with 1) a bid for the following class of persons: companies and investment funds investing on a regular basis in "small cap" securities (including, without limitation, any FCPI, FCPR or FIP) in the health, biotechnology, software or information technology sector, up to a maximum of 50 subscribers and for a unit investment exceeding 100,000 euros (including issue premium); and 2) an offer to qualified investors or a restricted circle of investors referred to in II of Article L 411-2 of the Monetary and Financial Code.

The new shares will carry current rights and will be immediately admitted to trading on the Alternext Paris regulated market under ISIN code FR0010908723 ALINT on Tuesday, February 7, 2017.

As part of the capital increase, IntegraGen has entered into a forbearance and retention commitment for the Company's 90-day shares as of February 7, 2017, subject to certain customary exceptions.

The share capital of IntegraGen will be composed of 6,536,944 shares. By way of indication, the participation of a shareholder holding 1.00% of the share capital of the company prior to the issue will be increased to 0.78%.

### **Information available to the public**

The current transaction did not give rise to the issue of a prospectus submitted for approval by the Autorité des marchés financiers (AMF).

The placement was led by Portzamparc BNP Paribas as Lead Partner and Bookrunner.

“The success of this capital increase demonstrates investor confidence in IntegraGen's outlook,” stated Laurence Riot Lamotte, IntegraGen’s Chief Financial Officer. “After completing this transaction, the company has the means to accelerate its developments in clinical genomics and diagnostics, and in particular, the commercial launch of our miRpredX test in the coming months.”

### **About IntegraGen**

IntegraGen is a company specializing in deciphering the human genome and producing relevant and easily interpretable data for academic and private laboratories. IntegraGen’s oncology efforts provide researchers and clinicians with sophisticated tools for analysis and therapeutic individualization of treatment approaches allowing them to tailor therapy to the genetic profiles of patients. As of December 31, 2016, IntegraGen had 38 employees and had generated revenue of €6.0 million in 2016. Based in Evry Genopole, IntegraGen also has an U.S. office in Cambridge, Massachusetts. IntegraGen is listed on Alternext of Euronext Paris (ISIN: FR0010908723 - Ticker: ALINT - PEA-SME).

For more information on IntegraGen visit [www.integragen.com](http://www.integragen.com).

### **Contacts**

#### **IntegraGen**

Bernard COURTIEU  
President and CEO

Laurence RIOT LAMOTTE  
Chief Financial Officer

[contact@integragen.com](mailto:contact@integragen.com)

Tel: +33 (0)1 60 91 09 00

#### **NewCap**

Investors relations

Emmanuel HUYNH

Louis-Victor DELOUVRIER

[integragen@newcap.eu](mailto:integragen@newcap.eu)

Tel: +33 (0)1 44 71 98 53